IL2 and cancer: The use of much lower doses of interleukin-2 (IL-2) than employed in cancer therapy has shown clinical efficacy in a number of inflammatory and autoimmune conditions, by stimulating a subset of CD4+ T cells expressing high levels of the high-affinity trimeric IL-2 receptor, designated as regulatory T (Treg) cells1–11.